• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sofosbuvir-velpatasvir shows promise in HCV genotype 2 and 3 infection: The ASTRAL 2-3 study

byDavid ArsaniousandShaidah Deghan, MSc. MD
November 18, 2015
in Chronic Disease, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among patients with hepatitis C virus (HCV) genotype 2 or 3, 12 weeks of treatment with a once-daily, fixed-dose, combination tablet of sofosbuvir-velpatasvir resulted in rates of sustained virologic response compared to those treated with standard therapy.

2. The results from this study provide the potential for using ribavirin-free regimens given the knowledge that ribavirin has a high side effect profile.

Evidence Rating Level: 1 (Excellent)

Study Rundown: This is a report of two randomized, controlled trials involving patients with HCV genotype 2 and 3 infection, including patients with compensated cirrhosis. In the HCV genotype 2 trial, patients were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 weeks or sofosbuvir plus weight-based ribavirin for 12 weeks. In the HCV genotype 3 trial, patients were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 weeks or sofosbuvir-ribavirin for 24 weeks. The results showed that Sofosbuvir-velpatasvir demonstrated a significantly higher rate of sustained virologic response than sofosbuvir-ribavirin at 12 weeks after the end of therapy in patients chronically infected with HCV genotype 2 and 3.

These studies drew strength from their randomized, controlled design and successfully meeting their target of enrolling 20% of patients that had compensated cirrhosis. However, they are limited by the investigators, patients, and trial personnel being aware of the treatment assignments at all points in the two trials. The generalizability of these results may be limited by the exclusion of patients with decompensated liver disease and the small number of black patients who were enrolled, as a result of the low prevalence of HCV genotype 2 or 3 infection among blacks in certain regions, including the United States.

Click to read the study, published today in NEJM

Relevant Reading: A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus

RELATED REPORTS

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

In-Depth [randomized controlled trial]: This study includes two multicenter trials, in which patients with chronic HCV infection were randomized in a 1:1 ratio to receive a fixed dose combination tablet containing 400 mg sofosbuvir + 100 mg velpatasvir OD for 12 weeks or 400 mg sofosbuvir OD and ribavirin (1000 mg in patients <75 kg and 1200 mg in patients ≥ 75 kg) BID for 12 weeks for patients with HCV genotype 2 or 24 weeks for patients with HCV genotype 3.

The primary end point for the HCV genotype 2 and HCV genotype 3 trial was a sustained virologic response, which was defined as an HCV RNA level of less than 15 IU/mL at 12 weeks after the end of treatment. Among HCV genotype 2 infected patients who underwent randomization and began treatment, a significantly higher number of those treated with sofosbuvir-velpatasvir for 12 weeks (99%; 95% [CI], 96 to 100%) demonstrated a sustained virologic response 12 weeks after the end of treatment versus patients who were treated with sofosbuvir-ribavirin for 12 weeks (94%; 95% [CI], 88 to 97%) (p=0.02). Among HCV genotype 3 infected patients who underwent randomization and began treatment, a significantly higher number of those treated with sofosbuvir-velpatasvir for 12 weeks (95%; 95% [CI], 92 to 98%) demonstrated a sustained virologic response 12 weeks after the end of treatment compared to those treated with sofosbuvir-ribavirin for 24 weeks (80%; 95% [CI], 75 to 85%) (p < 0.001).

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hepatitis CSofosbuvir-velpatasvir
Previous Post

Voriconazole superior to amphotericin B for invasive aspergillosis [Classics Series]

Next Post

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

RelatedReports

Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

February 10, 2021
Screening insufficient for newborns exposed to hepatitis C virus
Cardiology

Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C

December 28, 2019
Next Post
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men

Community treatment of HIV pre-exposure prophylaxis demonstrated low acquisition rate but disparities in adherence

Non-invasive prenatal testing linked to decreased diagnostic testing

New data on prevalence and spectrum of germline mutations in pediatric cancer patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.